Form 4: Fulgent Genetics CSO Reports RSU Vesting, Tax Withholdings

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, reported the vesting of various restricted stock units and associated tax withholdings, resulting in a net increase in beneficial ownership.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported multiple equity transactions.
• On February 23, 2026, 403 shares of Common Stock were withheld to satisfy tax obligations from the vesting of restricted stock units granted on February 23, 2023, at a price of $23.01 per share.
• On February 24, 2026, performance-based restricted stock units vested, resulting in the acquisition of 4,891 shares (granted Feb 23, 2023), 12,762 shares (granted Feb 26, 2024), and 22,806 shares (granted Feb 25, 2025), all at a price of $0.
• Also on February 24, 2026, shares were withheld for tax obligations related to the vesting of performance-based RSUs: 2,489 shares (from Feb 23, 2023 grant) at $23.09, 4,661 shares (from Feb 26, 2024 grant) at $23.09, and 8,149 shares (from Feb 25, 2025 grant) at $23.09.
• Additionally, on February 24, 2026, 26,661 restricted stock units were acquired, which will vest over a period of three years, with the first 1/3rd vesting 12 months after March 1, 2026.
• Following these transactions, Hanlin Gao's direct beneficial ownership of Common Stock increased to 1,002,977 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. While shares were withheld for taxes, the net effect is an increase in the Chief Scientific Officer's beneficial ownership due to RSU vestings and a new grant, aligning executive interests with long-term shareholder value.

Positives

• Hanlin Gao's beneficial ownership of Fulgent Genetics Common Stock increased to 1,002,977 shares.
• Multiple tranches of performance-based restricted stock units vested, indicating the achievement of certain performance milestones.
• A new grant of 26,661 restricted stock units was issued, aligning management's long-term interests with shareholders.

Negatives

• A total of 15,702 shares (403 + 2,489 + 4,661 + 8,149) were withheld to cover tax withholding obligations related to RSU vestings.

Future Outlook

The newly granted 26,661 restricted stock units are scheduled to vest over a three-year period, with the first 1/3rd vesting 12 months after March 1, 2026, and subsequent 1/12th portions vesting every three months thereafter, contingent on continued service.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4 provide transparency into executive equity movements, which can sometimes signal management's confidence or lack thereof in the company's future prospects. In this case, the transactions reflect routine compensation events rather than discretionary open market purchases or sales.

Stakeholder Impact

• Shareholders: Increased insider ownership can be seen as a positive signal, aligning management's interests with shareholder value creation.
• Employees: The vesting of performance-based RSUs demonstrates the company's commitment to its compensation plans and the achievement of internal milestones.

Next Steps

• Continued vesting of the 26,661 restricted stock units over the next three years, subject to continued service.
• Future reporting of additional RSU vestings and tax withholdings as per the established compensation schedule.

Key Dates

Recommendation

This Form 4 details routine, pre-scheduled equity compensation events for a key executive, including RSU vestings and associated tax withholdings, along with a new RSU grant. Such transactions are standard and do not typically provide new material information that would warrant a change in investment recommendation. The net increase in beneficial ownership is a minor positive, but not significant enough to alter the fundamental outlook or investment thesis for Fulgent Genetics.

Keywords

Fulgent Genetics, FLGT, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Scientific Officer, Beneficial Ownership, Tax Withholding